Abstract
The most common site of metastases in breast cancer patients is bone with reported incidence around 60–80 %. The skeletal metastases are associated with increased morbidity, but studies have noted a better overall survival compared to patients with visceral organ metastases. Imaging plays a key role in the diagnosis and assessment of bone metastases in clinical practice and trials. The commonly used RECIST 1.1 criteria recognize challenges of assessing bone metasteses. Bone lesions are mainly considered unmeasurable and qualitatively assessed, except in the presence of osteolytic lesions with measurable soft tissue component.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
